Free Newsletter
Register for our Free Newsletters
Analysis, Inspection and Laboratory
Assisted/Independent Living
Clinical and Nursing Equipment
Design and Manufacture of Medical Equipment
Diagnostics Equipment, Monitoring and Test
Education, Training and Professional Services
Health Education and Patient Management
Health Estates Management
Healthcare Support and Information Services
Hygiene and Infection Control
IT and Communications in Healthcare
Medical Device Technology
Research and Development
Safety and Security
View All
Other Carouselweb publications
Carousel Web
Defense File
New Materials
Pro Health Zone
Pro Health Zone
Pro Security Zone
Web Lec
Pro Engineering Zone

Rapid result gram positive microbiology tests receive FDA clearance

Dade Behring : 09 October, 2007  (New Product)
Dade Behring has received clearance from the US Food and Drug Administration (FDA) for use of its MicroScan Synergies plus Gram-positive panels.
The new technology used in the panels allows for rapid two hour identification of bacteria and same day test results for detecting certain antibiotic-resistant bacteria that cause serious health threats in a hospital environment.

Some of the antibiotic-resistant bacteria that may be identified on the same-day tested are:

- Methicillin-resistant Staphylococcus aureus (MRSA),
- Vancomycin-resistant Staphylococcus aureus (VRSA), and
- Vancomycin-resistant Enterococcus.

According to the Centers for Disease Control and Prevention (CDC), antibiotic resistance is one of the world's most pressing public health issues. Antibiotic resistance prolongs illness in patients and puts them at a greater risk of death. It also increases the cost of health care resulting from more hospital admissions, longer hospital stays and the use of expensive antibiotics.

'Dade Behring feels strongly about addressing this global health issue and continues to develop automated microbiology tests that identify the latest antibiotic-resistant bacteria,' said Jim Reid-Anderson, chairman, president and CEO, Dade Behring. 'By more quickly confirming the diagnosis of an antibiotic-resistant infection, physicians can treat patients and mitigate life-threatening infections from spreading to others in the hospital environment.'

With the addition of Synergies plus Gram-positive panels, the company now offers automated solutions for rapid identification and same day detection of antibiotic-resistant bacteria, both for Gram-positive and Gram-negative bacteria. This is especially important as more strains of bacteria become resistant to antibiotics.

For example, in 1971, the Centers for Disease Control and Prevention (CDC) reported only two percent of staphylococcus infections as resistant to the antibiotic methicillin. This number increased to 22 percent in 1995 and nearly 63 percent in 2004, resulting in an increase in the use of the antibiotic vancomycin. The growing dependency on vancomycin led to the emergence of vancomycin-resistant S aureus and enterococcus infections, posing a threat to health care environments and demonstrating a global trend that is expected to continue.

The introduction of these new MicroScan panels secures Dade Behring's leadership position in automated identification and antimicrobial susceptibility testing, which is complemented by a worldwide reputation for quality and accuracy in the detection of emerging antibiotic-resistant strains of bacteria.

Dade Behring has nearly 60 MicroScan panels of tests, with up to date antibiotics including overnight, rapid and specialty products. The company was the first to offer an automated identification and susceptibility testing system cleared for improved detection of the emerging resistant bacterium vancomycin-resistant Staphylococcus aureus (VRSA).
Bookmark and Share
Home I Editor's Blog I News by Zone I News by Date I News by Category I Special Reports I Directory I Events I Advertise I Submit Your News I About Us I Guides
   © 2012
Netgains Logo